Summary | |
---|---|
Symbol | FBLN2 |
Name | fibulin 2 |
Aliases | FIBL-2; Fibulin-2 |
Chromosomal Location | 3p25-p24 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Basic function annotation. > Subcellular Location, Domain and Function > Gene Ontology > KEGG and Reactome Pathway |
Subcellular Location | Secreted, extracellular space, extracellular matrix. |
Domain |
PF01821 Anaphylotoxin-like domain PF12662 Complement Clr-like EGF-like PF07645 Calcium-binding EGF domain |
Function |
Its binding to fibronectin and some other ligands is calcium dependent. May act as an adapter that mediates the interaction between FBN1 and ELN (PubMed:17255108). |
Biological Process |
GO:0010810 regulation of cell-substrate adhesion GO:0010811 positive regulation of cell-substrate adhesion GO:0031589 cell-substrate adhesion GO:0045785 positive regulation of cell adhesion |
Molecular Function |
GO:0005201 extracellular matrix structural constituent GO:0050840 extracellular matrix binding |
Cellular Component |
GO:0005578 proteinaceous extracellular matrix |
KEGG | - |
Reactome |
R-HSA-1566948: Elastic fibre formation R-HSA-1474244: Extracellular matrix organization R-HSA-2129379: Molecules associated with elastic fibres |
Summary | |
---|---|
Symbol | FBLN2 |
Name | fibulin 2 |
Aliases | FIBL-2; Fibulin-2 |
Chromosomal Location | 3p25-p24 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content | Literatures that report relations between FBLN2 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells. |
There is no record. |
Summary | |
---|---|
Symbol | FBLN2 |
Name | fibulin 2 |
Aliases | FIBL-2; Fibulin-2 |
Chromosomal Location | 3p25-p24 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content | High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets. |
> High-throughput Screening
[ TOP ]
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Statistical results of FBLN2 in screening data sets for detecting immune reponses.
|
Summary | |
---|---|
Symbol | FBLN2 |
Name | fibulin 2 |
Aliases | FIBL-2; Fibulin-2 |
Chromosomal Location | 3p25-p24 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets. > Expression difference between responders and non-responders > Mutation difference between responders and non-responders |
Points in the above scatter plot represent the expression difference of FBLN2 in various data sets.
|
Points in the above scatter plot represent the mutation difference of FBLN2 in various data sets.
|
Summary | |
---|---|
Symbol | FBLN2 |
Name | fibulin 2 |
Aliases | FIBL-2; Fibulin-2 |
Chromosomal Location | 3p25-p24 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of FBLN2. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene. |
Summary | |
---|---|
Symbol | FBLN2 |
Name | fibulin 2 |
Aliases | FIBL-2; Fibulin-2 |
Chromosomal Location | 3p25-p24 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of FBLN2. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by FBLN2. > Immunoinhibitor > Immunostimulator > MHC molecule |
Summary | |
---|---|
Symbol | FBLN2 |
Name | fibulin 2 |
Aliases | FIBL-2; Fibulin-2 |
Chromosomal Location | 3p25-p24 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of FBLN2. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene. > Chemokine > Receptor |
Summary | |
---|---|
Symbol | FBLN2 |
Name | fibulin 2 |
Aliases | FIBL-2; Fibulin-2 |
Chromosomal Location | 3p25-p24 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Distribution of FBLN2 expression across immune and molecular subtypes. > Immune subtype > Molecular subtype |
Summary | |
---|---|
Symbol | FBLN2 |
Name | fibulin 2 |
Aliases | FIBL-2; Fibulin-2 |
Chromosomal Location | 3p25-p24 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Associations between FBLN2 and clinical features. > Overall survival analysis > Cancer stage > Tumor grade |